Decision on amending the marketing authorisation granted by Decision C(2022) 7342(final) for “Comirnaty - tozinameran, COVID-19 mRNA vaccine (nucleoside-modified)”, a medicinal product for human use

This procedure concerns an objection to a European Commission decision regarding the marketing authorisation for the COVID-19 vaccine Comirnaty. It follows specific parliamentary rules for scrutinising such decisions.

This affects the availability and regulation of the Comirnaty vaccine within the EU. It allows for parliamentary oversight of executive decisions on medicinal products.